{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-020335","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.064126+00:00","generated_at":"2026-06-01T04:14:30.822622+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024","bullets":["Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.","Topline data expected in December 2024 (16-week double-blind placebo-controlled period).","Trial targets up to 160 patients; excludes AD co-pathology via plasma ptau181 screen (two-thirds eligible).","Primary endpoint: Clinical Dementia Rating Sum of Boxes; funded by $21M NIH/NIA grant.","43 sites (32 US, 8 UK, 3 Netherlands) all initiated; open-label extension for 32 additional weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-020335","json":"https://secwatch.observer/filing/0001437749-24-020335.json","markdown":"https://secwatch.observer/filing/0001437749-24-020335.md","text":"https://secwatch.observer/filing/0001437749-24-020335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/0001437749-24-020335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924020335/crvo20240613_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:14:30.822622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}